Symbio Pharmaceuticals Limited (4582) AI Stock Analysis

• Market Cap: ¥7.02B
• Dividend Yield: N/A
• Average Volume (3M): 577.10K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.80
• Revenue Growth: -50.27%
• EPS Growth: -3.33%
• Country: JP
• Employees: 108
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -21.66
• Shares Outstanding: 59,567,080
• 10 Day Avg. Volume: 434,010
• 30 Day Avg. Volume: 577,100
• PEG Ratio: -0.08
• Price to Book (P/B): 3.55
• Price to Sales (P/S): 3.46
• P/FCF Ratio: -0.99
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: ¥123.00 ▲(36.67% Upside)
• Action: Reiterated Date: 03/17/26
• Date: Action: Reiterated 03/17/26

The score is primarily held down by weakened financial performance—multi-year revenue declines, deep losses, heavy cash burn, and increased leverage with equity erosion. Technicals are mixed with neutral-to-oversold signals providing only limited support, while valuation is constrained by negative earnings and no stated dividend yield.

Positive Factors

Focused specialty pharmaceutical portfolio (oncology/hematology)

Symbio’s focused specialty-pharma model—development, manufacturing/marketing and distribution concentrated on oncology and hematology, including marketed products such as TREAKISYM—creates durable clinical demand, regulatory barriers and customer stickiness that support recurring sales and long-term market positioning.

Diversified revenue mix: product sales plus licensing/collaborations

A business model that combines product sales with licensing and collaboration income provides durable optionality: upfronts and milestones can smooth funding, royalties create long-running cash streams, and partnerships share R&D and commercialization risk—supporting resilience over a multi-month to multi-year horizon.

Strong gross margins and meaningful asset base

Reported strong gross margins and a meaningful asset base indicate favorable product-level economics and tangible capacity (manufacturing/supply) that can underpin recovery. If SG&A and R&D spending are rebalanced, high gross margins provide a structural path to restore profitability and cash generation over months.

Negative Factors

Multi-year revenue decline

Sustained top-line declines across 2023–2025 shrink scale, reduce pricing leverage and weaken the economics of marketed products. Continued revenue contraction limits reinvestment in commercialization and R&D, risks partner disengagement, and makes returning to durable growth dependent on new product or deal catalysts.

Persistent negative operating and free cash flow

Material negative operating and free cash flows over multiple years force reliance on external financing or asset sales. This worsens liquidity risk, can drive dilution or higher-cost debt, and constrains sustainable funding for late-stage trials, commercialization and strategic investments absent a clear near-term improvement in cash generation.

New leverage and equity erosion

The emergence of ~¥2.0B debt after years of zero leverage materially raises financial risk. Debt above equity and compressed shareholders' equity reduce the company’s buffer against shocks, increase interest and refinancing obligations, and limit strategic flexibility for investments or licensing deals if operating losses persist.

Symbio Pharmaceuticals Limited Business Overview & Revenue Model

Company Description

SymBio Pharmaceuticals Limited engages in the research and development, manufacturing, and marketing of pharmaceutical drugs in the areas of oncology and hematology in Japan. It is involved in the development of Treakisym SyB L-0501, an anti-cancer agent, which is marketed for the treatment of non-Hodgkin's lymphoma, multiple myeloma, and chronic lymphocytic leukemia under the TREAKISYM name; and is in the Phase III clinical trial to treat relapsed/refractory diffuse large B-cell lymphoma. The company also engages in the development of SyB L-1701, a ready-to-dilute formulation; and SyB L-1702, a rapid infusion liquid formulation. In addition, it is involved in the development of SyB L-1101, an intravenous formulation, which is in Phase III clinical trial for the treatment of higher-risk myelodysplastic syndromes (HR-MDS); and SyB C-1101, an oral formulation that is in Phase II/III clinical trial in combination with Azacitidine to treat HR-MDS. Further, it engages in the development of SyB V-1901, an antiviral drug for the treatment of infectious diseases. SymBio Pharmaceuticals Limited was incorporated in 2005 and is based in Tokyo, Japan.

How the Company Makes Money

Symbio Pharmaceuticals makes money primarily by commercializing prescription pharmaceuticals. Key revenue streams include: (1) Product sales of marketed drugs in Japan—revenue is generated when Symbio (or its commercialization partners, depending on product/territory and agreement structure) sells approved medicines to wholesalers/medical institutions. (2) Licensing and collaboration income—Symbio has historically used in-licensing/out-licensing and partnership structures for development and/or commercialization; depending on contract terms, this can generate upfront payments, milestone payments tied to development/regulatory/commercial events, and ongoing royalties on partner sales. (3) Other related income can include manufacturing/supply-related receipts where Symbio supplies finished product or active ingredients under agreed pricing; however, specific arrangements and their materiality are not available here. Detailed product-by-product revenue contribution, named current partners, and the exact split between product sales vs. licensing/milestones are null.

Symbio Pharmaceuticals Limited Financial Statement Overview

Summary

Financials have deteriorated sharply: revenue declined materially in 2023–2025, profitability swung from positive (2021–2022022) to deeply negative margins (2023–2025), and operating/free cash flow are meaningfully negative with heavy cash burn in 2024–2025. Added pressure comes from new leverage in 2025 (~¥2.0B debt; debt-to-equity ~1.56x) alongside a shrinking equity base. Strong gross margin is a partial offset but has not translated into earnings or cash generation.

Income Statement

Profitability has deteriorated materially after a strong 2021–2022 period. Revenue fell sharply in 2025 (down ~28% year over year) following declines in 2023–2024, and the company swung from solid positive margins in 2021–2022 to deeply negative operating and net margins in 2023–2025. While gross margin remains high, it has not translated into bottom-line profits, indicating a heavy cost burden outside of direct production (e.g., selling, R&D, or other operating costs).

Balance Sheet

The balance sheet shows increased financial risk versus prior years. Total debt rose to ~¥2.0B in 2025 after being zero in 2021–2024, pushing debt above equity (debt-to-equity ~1.56x). Equity has also compressed significantly from 2022–2024 levels, consistent with sustained losses, and returns on equity are sharply negative in 2023–2025. Offsetting this, the company still reports a meaningful asset base, but leverage and equity erosion reduce flexibility.

Cash Flow

Cash generation is a key weakness. Operating cash flow and free cash flow are meaningfully negative in 2023–2025, with an especially large cash burn in 2024–2025. The business is not funding itself from operations, and cash flow has moved in the same direction as earnings (loss-making years paired with cash outflows), raising reliance on external financing and heightening liquidity risk if losses persist.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.82B	1.31B	2.45B	5.59B	10.01B	8.25B
Gross Profit	1.37B	947.34M	1.87B	4.41B	7.60B	5.80B
EBITDA	-4.61B	-4.60B	-3.78B	-714.00M	2.06B	1.11B
Net Income	-4.66B	-4.78B	-3.83B	-1.96B	1.18B	2.03B
Balance Sheet
Total Assets	4.14B	3.87B	4.97B	8.17B	17.43B	15.18B
Cash, Cash Equivalents and Short-Term Investments	3.05B	2.88B	3.96B	6.52B	6.28B	3.86B
Total Debt	1.30B	1.98B	0.00	0.00	0.00	0.00
Total Liabilities	1.78B	2.60B	770.77M	8.14B	8.92B	8.43B
Stockholders Equity	2.36B	1.27B	4.20B	7.21B	8.51B	6.75B
Cash Flow
Free Cash Flow	0.00	-4.58B	-3.44B	-427.48M	1.57B	76.20M
Operating Cash Flow	0.00	-4.58B	-3.42B	-194.69M	1.61B	140.04M
Investing Cash Flow	0.00	-75.92M	-3.96M	-376.70M	-47.13M	-70.85M
Financing Cash Flow	0.00	3.62B	708.47M	680.16M	627.99M	-71.92M

Symbio Pharmaceuticals Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 90.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4582, the sentiment is Neutral. The current price of 90 is below the 20-day moving average (MA) of 136.55, below the 50-day MA of 110.16, and below the 200-day MA of 130.03, indicating a neutral trend. The MACD of 0.01 indicates Positive momentum. The RSI at 48.35 is Neutral, neither overbought nor oversold. The STOCH value of 29.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4582.

Symbio Pharmaceuticals Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4574	66 Neutral	¥14.72B	16.22	―	―	-5.41%	―
4539	64 Neutral	¥6.33B	11.64	―	3.21%	4.25%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4597	51 Neutral	¥8.74B	-13.67	-90.96%	―	243.16%	-23.00%
4512	48 Neutral	¥12.11B	7.11	―	1.06%	5.42%	-62.03%
4586	45 Neutral	¥6.41B	-10.38	―	―	-52.41%	-80.31%
4582	43 Neutral	¥7.02B	-0.95	―	―	-50.27%	-3.33%

Symbio Pharmaceuticals Limited Corporate Events

SymBio Pharmaceuticals’ Losses Deepen as Equity Thins Despite 2026 Sales Rebound Forecast

SymBio Pharmaceuticals reported a steep decline in consolidated net sales for fiscal 2025 to ¥1.31 billion, down 46.7% year-on-year, alongside widening operating and net losses, with profit attributable to owners of parent falling to a loss of ¥4.78 billion. The company’s financial position deteriorated markedly, with total assets shrinking, equity ratio plunging from 78.1% to 23.9%, and net assets per share dropping sharply, underscoring growing balance sheet pressure despite positive cash flow from financing activities and the continued suspension of dividends. For fiscal 2026, SymBio forecasts a near-tripling of net sales to ¥3.89 billion but still expects substantial operating and bottom-line losses, signaling that while revenue is projected to recover, profitability remains distant and capital structure risk will continue to be a key concern for investors and creditors.

The most recent analyst rating on (JP:4582) stock is a Sell with a Yen85.00 price target. To see the full list of analyst forecasts on Symbio Pharmaceuticals Limited stock, see the JP:4582 Stock Forecast page.